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A B S T R A C T 
Dronedarone is a non-iodinated analogue of the Class III antiarrhythmic agent amiodarone.  It exerts potent 
inhibition of “hERG” potassium channels that underpin the cardiac rapid delayed rectifier potassium current, 
IKr.  This study aimed to extend understanding of interactions between dronedarone and the hERG channel. 
Whole-cell patch-clamp recordings were made at 37C of hERG channel current (IhERG) from HEK-293 
cells expressing wild-type (WT) hERG or alanine mutants of residues in the channel’s pore-helix/selectivity 
filter region (T623, S624, V625) or S6 helices (S649, Y652, F656, V659). Molecular docking simulations 
were performed using a cryo-EM structure of hERG and a MthK-based homology model. The half-maximal 
inhibitory (IC50) value for WT IhERG inhibition by dronedarone was 42.6 ± 3.9 nM (n= at least 5 cells for 
each of 6 concentrations).  600 nM dronedarone exerted reduced WT IhERG block when the direction of K
+ 
flux was reversed, consistent with interactions between the drug and permeant ion.  In contrast with recently 
reported data for amiodarone, the S624A mutation did not attenuate IhERG blockade, whilst T623A and 
V625A channels exhibited modestly attenuated block. The S649A mutation was without significant effect 
and the Y652A and F656A mutations exhibited modest reductions in block.  The V659A mutation produced 
the most marked effect on dronedarone action.  Docking simulations were generally consistent with modest 
interactions with canonical binding residues and suggested an indirect rather than direct effect of the V659A 
mutation on the drug’s action. These findings leave open the possibility that as yet unexplored residue(s) 
could act as key determinants of high affinity hERG channel block by dronedarone. 
 
© 2018 The authors. Hosting by Science Repository. All rights reserved.    
 
Introduction 
The cardiac rapid delayed rectifier potassium current, IKr is critical for 
normal ventricular repolarization [1].  The channels underlying IKr are 
encoded by hERG (human ether-à-go-go Related Gene; alternative 
nomenclature KCNH2) [2,3]. Loss-of-function hERG mutations underlie 
the LQT2 form of congenital long QT syndrome, whilst gain-of-function 
mutations give rise to the SQT1 form of congenital short QT syndrome 
[4, 5].  IKr/hERG channels are also key drug targets in the heart: they 
represent the major potassium channel target for a number of 
antiarrhythmic drugs and are also sensitive to pharmacological inhibition 
by structurally and therapeutically diverse drugs that are associated with 
the drug-induced (acquired) form of long QT syndrome [4, 6, 7]. 
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Amiodarone is one of the most effective antiarrhythmic drugs in clinical 
use.  It can be used in patients with structural heart disease and be helpful 
in long term treatment of atrial fibrillation (AF) [8]. Intravenous 
amiodarone is valuable in the treatment of life-threatening ventricular 
arrhythmias [9]. Amiodarone exerts Class I-IV antiarrhythmic actions 
through effects on multiple targets [10, 11].  Unfortunately, amiodarone 
can produce a number of extra-cardiac side effects, some of which may 
result from the incorporation of iodine in its structure; dronedarone is a 
non-iodinated benzofuran analogue of amiodarone that was developed 
to retain antiarrhythmic effectiveness whilst reducing unwanted side 
effects [11, 12].  Dronedarone is an effective inhibitor of native cardiac 
IKr and in experiments on recombinant hERG and KCNQ1+KCNE1 
channels (representing respectively IKr and IKs) dronedarone was 
observed to show selectivity for hERG over KCNQ1+KCNE1 [13-15].  
When tested against hERG in a mammalian expression system, 
dronedarone inhibited hERG current (IhERG) with a half-maximal 
inhibitory concentration (IC50) below 100 nM, making it a high potency 
hERG channel inhibitor [16]. 
 
The archetypal high affinity Class III drug hERG inhibitors come from 
the methanesulphonanilide class (which includes dofetilide, MK499 and 
E-4031).  Experiments with these agents have revealed key drug binding 
determinants on the S6 helices and pore-helix/close to the selectivity 
filter [17, 18].  Prominent amongst these are two S6 aromatic residues, 
Y652 and F656, mutation of which drastically reduces 
methanesulphonanilide binding [17, 18].  Indeed, for the majority of 
drugs examined in detail one or both of these aromatic residues have 
been found to be key binding determinant(s) [4, 7].  Experiments on 
dronedarone, however, showed that a “profound” IhERG blocking 
concentration (>65-fold the wild-type channel IC50) was able effectively 
to inhibit hERG channels in which Y652 or F656 had been mutated, 
raising questions regarding the dronedarone binding site on hERG [16].  
Recently, we published a detailed analysis of binding to hERG of 
structurally related amiodarone, showing that amiodarone can bind 
within the hERG channel pore [19], but that the relative importance of 
particular binding residues differs from that previously reported for other 
high affinity agents [17-19]. To complement this, the purpose of the 
present study was to evaluate the impact on dronedarone’s inhibition of 
IhERG of a total of 7 mutations of pore-helix and S6 residues implicated 
in drug binding.  Our results provide further evidence of variation in 
overall composition of the binding site(s) for different hERG blocking 
drugs. 
 
Materials and Methods 
 
Mutagenesis 
 
The residues examined in this study are highlighted in Figure 1A. 
Alanine mutants of hERG at the base of the pore helices near the 
selectivity filter (T623A, S624A, V625A) and the S6 helix (S649A, 
V659A), were constructed using the QuickChange® site-directed 
mutagenesis kit (Stratagene, La Jolla, CA) as previously reported [19-
21].  Mutations were confirmed by sequencing the entire open reading 
frame (Eurofins MWG Operon, Ebersberg, Germany). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: (A) Sequence alignment for hERG and the MthK channel, highlighting the pore helix and S6 transmembrane domains. The residues of hERG 
analysed in this study by alanine mutagenesis are underlined. Bottom row of symbols highlights amino acid identities (-) and strong similarities (:). Amino 
acids in grey font have side chains facing the pore cavity of the MthK structure. Note that the last four residues of S6 in the MthK structure italicised (INRE) 
are not seen in the crystal structure and aren’t included in the hERG model.  
(B) Representative traces of WT IhERG elicited by voltage protocol (lower panel, start to start interval between successive application was 12s) in control 
solution and after reaching steady-state, 10 minutes following exposure to 30nM Dronedarone (Droned).  
(C) Concentration-response relationship for inhibition of WT IhERG by Droned, with fractional block values corrected for run-down as indicated in the 
Methods. The half-maximal inhibitory (IC50) value for IhERG inhibition by Droned was 42.6 ± 3.9 nM and Hill -coefficient was 0.93±0.07 (n= at least 5 cells 
for each of 6 concentrations tested).  
(D) Bar chart comparing the mean fractional block of outward and inward WT IhERG tails in 4mM [K
+] and in 94mM [K+] produced by 600nM Droned, *** 
p < 0.001, one-way ANOVA followed by Bonferroni’s post-test. 
 
A 
B 
C D 
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Maintenance of mammalian cell lines and cell transfection 
 
HEK 293 cells (European Collection of Cell Cultures, Porton Down, 
UK) were maintained at 37 °C, 5% CO2 in Dulbecco's minimum 
essential medium with Glutamax-1 (DMEM; Gibco, Paisley, UK). This 
was supplemented with 10% foetal bovine serum (Gibco, Paisley, UK). 
Cells were transiently transfected with cDNA plasmids encoding wild-
type (WT) and mutant hERG using Lipofectamine 2000 (Invitrogen, 
Paisley, UK) according to the manufacturer's instructions. Expression 
plasmid encoding CD8 was also added (in pIRES, donated by Dr I Baró, 
University of Nantes, France) to be used as a successful marker of 
transfection. Recordings were performed 24–48 h after transfection. 
Successfully transfected cells (positive to CD8) were identified using 
Dynabeads® (Invitrogen, Paisley, UK) [19- 22]. 
 
The HEK 293 cell lines stably expressing mutant F656A and Y652A 
hERG created in our laboratory have been previously reported [23]. 
Cells were passaged using enzyme free cell dissociation solution 
(Millipore, Watford, UK) and plated onto sterilised 13-mm glass 
coverslips in 40-mm petri dishes containing DMEM, which was 
supplemented with 10% foetal bovine serum, 100 µg/mL of hygromycin 
[19, 23]. 
 
Solutions, electrophysiological recordings, experimental 
protocol and data analysis 
 
Measurements of hERG current (IhERG) were made at 37 ± 1 °C as 
described previously [19-21]. Cells were superfused in the recording 
chamber with normal Tyrode’s solution containing (in mM): 140 NaCl, 
4 KCl, 2.5 CaCl2, 1 MgCl2, 10 Glucose, and 5 HEPES (titrated to pH of 
7.45 with NaOH). Patch-pipettes (Corning 7052 glass, AM Systems, 
Carlsborg, USA) were pulled and heat-polished (Narishige MF83, 
Tokyo, Japan) to 2.5–4 MΩ; pipette dialysate contained (in mM): 130 
KCl, 1 MgCl2, 5 EGTA, 5 MgATP, 10 HEPES (titrated to pH 7.2 using 
KOH) [19-21]. Dronedarone HCl (Sequoia Research Products Ltd, 
Pangbourne,UK)  was dissolved in ethanol to produce a stock solution 
of 50 mM, which was serially diluted to produce stock solutions ranging 
from 50 mM to 5 μM. The stock solutions were then diluted 1:1000-fold 
with Tyrode’s solution to achieve concentrations stated in the results 
section. 
 
Whole cell patch clamp recordings of membrane currents were made 
using an Axopatch 200A amplifier (Axon Instruments, Foster City, CA, 
USA) and a CV201 head stage. Between 70% and 80% of the electrode 
series resistance could be compensated. Data were recorded via a 
Digidata 1440A interface (Molecular Devices, Sunnyvale, CA, USA) 
and stored on the hard disk of a personal computer. Data digitization 
rates were 10 kHz during voltage protocols, and a bandwidth of 2 kHz 
was set on the amplifier. 
 
As in previous similar structure function studies [19-21,24,25], 
activating voltage commands to +20 mV were used, with tail currents 
observed at either −40 mV, or −120 mV (for T623A, V625A, F656A, 
V659A). High external 94 mM [K+] (with NaCl concentration 
correspondingly reduced) conditions were used for comparatively poorly 
expressing mutations (T623A and F656A). For all mutants studied, 
block levels were attained by repetitive stimulation for 10 min and 
fractional inhibition of IhERG tails measured. The data for each mutant 
were compared with WT IhERG studied under comparable conditions [19-
21, 24, 25]. 
 
Data were analysed using Clampfit 10.3 (Molecular Devices (UK) 
Limited, Wokingham, UK), Excel 2013 (Microsoft, Redmond, WA), 
Origin 7 (OriginLab Corporation, Northampton, MA, USA), and 
Graphpad Prism 7.0 (Graphpad Inc, La Jolla, CA, USA) software. The 
data are presented as the mean ± standard error of the mean (SEM). 
Statistical comparisons were made using a one-way analysis of variance 
(ANOVA) followed by a Bonferroni post-test, as appropriate. p values 
< 0.05 were taken as being statistically significant. 
 
Concentration–response data and correction for IhERG run-
down 
 
The fractional block (FB) of IhERG “tails” by the different drug 
concentrations studied was determined using the equation: 
Fractional block = 1 - ((IhERG-Droned)/IhERG-control)     (1) 
where “Fractional block” refers to the degree of inhibition of hERG 
current by a given concentration of Dronedarone. IhERG-
Droned and IhERG-control represent “tail” current amplitudes in the 
presence and absence of dronedarone. 
Concentration–response data were fitted by a standard Hill equation of 
the form: 
Fractional block = 1/ (1 + (IC50/[Droned])
 h)      (2) 
where IC50 is [Droned] producing half-maximal inhibition of 
the IhERG tail and h is the Hill coefficient for the fit. 
 
Like amiodarone and its relatives, dronedarone is lipophilic and exhibits 
a progressive development of IhERG blockade, reaching a stable level of 
block by ∼10 min of drug exposure, with continuous application 
throughout this period of the voltage protocol [16, 19, 26]. During this 
period, there was some overlying rundown of IhERG. Therefore, to correct 
IhERG rundown we adopted a method used previously [19, 26], in which 
we subtracted 12.8% (representing the mean rundown recorded over 10 
minutes in control experiments) of current magnitude from the last tail 
current in the control periods and used the resulting value to calculate 
fractional block following (10 min) exposure to dronedrone. 
 
Computational docking simulations 
 
Docking simulations were done using the recent open pore cryo-EM 
structure of a hERG construct (PDB: 5VA1) [27] and an open pore 
homology model of hERG constructed on the structure of MthK (PDB: 
1LNQ) [28] as described previously [29-30]. Docking was performed 
using GOLD version 5.6 (Cambridge Crystallographic Data Centre, 
Cambridge, UK) with the ChemPLP scoring function as described 
previously [30]. 
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Table 1: Summary data showing mean fractional block levels for WT and mutant hERG channels with 600 nM dronedarone. 
 
Results 
 
WT IhERG inhibition by dronedarone 
 
A standard voltage step protocol, comprised of a 2-second depolarization 
to + 20 mV followed by repolarization to − 40 mV was used to elicit 
IhERG tails [19, 21, 26]. Tail current amplitude was measured relative to 
current elicited by a brief (50 ms) pre-pulse prior to the + 20 mV test 
command [19, 21, 26].  Figure 1B shows example traces of IhERG in 
control and in the presence of 30nm dronedarone (giving 47% blockade 
of the IhERG tail for this cell, following run-down correction). A total of 
6 dronedarone concentrations were tested (extending concentration-
response information previously based on 5 concentrations) [22]. Figure 
1C shows the mean concentration-response relation for WT IhERG (with 
fractional block at each concentration plotted against the Log 
[Dronedarone]). The data were fitted with equation 2 (Materials and 
Methods), yielding IC50 and Hill co-efficient values of 42.6 ± 3.9 nM 
and 0.9±0.07. 
 
We then performed experiments in which the direction and magnitude 
of K+ flux was altered.  Figure 1D shows that 600 nM dronedarone 
produced a substantial fractional block of 0.97±0.01 (n=5) for outward 
IhERG tails in 4 mM [K
+]e. Consistent with a previous report [16], when 
measuring inward IhERG tails at -120 mV in lower panel in Figure 2A, the 
extent of inward IhERG tail inhibition by 600 nM dronedarone was less 
extensive than that seen for the outward tail current, fractional block  
reduced to 0.82±0.02 (n=5), and reduced even further to 0.75±0.01 (n=5) 
for inward IhERG tails in raised 94 mM K
+ respectively (both p<0.001 
compared with outward current in 4mM [K+], data summarised in Figure 
1D and Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Representative IhERG traces from WT hERG (left panel of Figure 2A, B, C) and pore helix mutant T623A (middle panel of A), S624A (middle 
panel of B) and V625A (middle panel of C) in the absence and presence (following 10 min exposure) of 600nM of dronedarone (Droned) recorded under 
the same recording condition by using the same voltage protocol shown in each lower panel. Inward currents were elicited by the voltage protocol as shown 
as an inset to left panel of A.  The expanded traces (and corresponding portion of the voltage protocol) are shown for clarity of display.  The right panel of 
A, B and C show bar charts displaying the mean fractional block of mutant compared with its WT control.  Statistical significance of comparisons of these 
values is given in Table 1. 
Channel Voltage step K+ numbers  Fractional block p value 
 mV mM     Mean ±SE  
WT-1 -40 4 5 0.97±0.01  
WT-2 -120 4 5 0.82±0.02 p<0.001 v WT-1 
WT-3 -120 94 5 0.75±0.01 p<0.001 v WT-1 
T623A -120 94 5 0.58±0.04 p<0.01 v WT-3 
S624A -40 4 5 0.92±0.02 p>0.05 v WT-1 
V625A -120 4 5 0.63±0.03 p<0.05 v WT-2 
S649A -40 4 6 0.93±0.02 p>0.05 v WT-1 
Y652A -40 4 6 0.76±0.06 p<0.005 v WT-1 
F656A -120 94 5 0.46±0.04 p<0.001 v WT-3 
V659A -120 4 5 0.36±0.07 p<0.0001 v WT-2 
A 
B 
C 
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Effects of pore helix mutations on IhERG inhibition by 
dronedarone 
 
Amino acids located at the base of the pore helix (T623, S624 and V625) 
have been identified as important components of drug-binding sites for 
some hERG blockers [18,19,31-33].  To investigate the roles of these 
residues in dronedarone block of IhERG, the T623A, S624A and V625A 
mutations were studied.  As previously [19], the T623A mutant was 
studied by measuring the inward IhERG tail current at −120 mV in raised 
(94mM) [K+]e. WT and T623A inward IhERG  tails were recorded, with 
examples shown in Figure 2A  (WT, left panel; T623A, middle panel) in 
the absence and presence of  600nM dronedarone, after 10 minutes 
exposure,  with whole voltage  protocol  shown as left inset. The mean 
fractional block values are shown in the right panel of Figure 2A and are 
also given in Table 1, showing a modest but significant reduction in 
block for T623A IhERG.  Our previous report showed that the pore helix 
S624A mutant produced substantial attenuation of the blocking effect of 
the structurally related hERG blocker amiodarone [19]. The effect of 
S624A hERG on IhERG block by dronedarone is shown in Figure 2B, in 
which block of WT IhERG (left panel) and S624A IhERG (middle panel) with 
the standard protocol were compared by recording outward hERG 
current in normal 4mM [K+] e. As shown in the representative traces and 
mean data (Figure 2B right panel), and summarised in Table 1, there was 
no significant effect of the S624A mutation on IhERG block by 
dronedarone.  V625 is located within the K+ signature sequence of hERG 
(SVGFG) and mutation to alanine reduces the selectivity of hERG 
channel for K+.  This mutant requires to be studied by measuring the 
inward hERG tail current at −120 mV (e.g. [19]). Figure 2C contains 
representative traces for WT (left panel) and V625A (middle panel) IhERG 
inhibition by dronedarone, with mean data shown in the bar graph in the 
right panel of Figure 2C and summarised in Table 1. The V625A 
mutation produced a modest, but significant reduction in dronedarone 
action. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Representative IhERG traces from WT-hERG (left panel of A, B, C) and S6 mutants S649A (middle panel of A), Y652A (middle panel of B) and 
F656A (middle panel of C) in the absence and presence (following 10 min exposure) of 600nM of dronedarone (Droned) elicited by the voltage protocol 
shown as lower traces in each panel. The right panels of A, B and C show bar charts displaying the mean fractional block of mutant compared with its WT 
control.  Statistical significance of comparisons of these values is given in Table 1 
 
IhERG inhibition of the S6 pore helix mutations by dronedarone 
 
The interaction between dronedarone with each of the S649A and 
Y652A hERG mutants was examined using the standard protocol and 
recording conditions [19]. Figure 3A shows representative traces for WT 
(left panel) and S649A (middle panel) IhERG in the absence and presence 
of 600 nM dronedarone, with mean data summarised in the bar chart in 
Figure 3A right panel and Table 1. There was no significant reduction in 
IhERG block with the S649A mutation. For the Y652A mutation (shown 
in Figure 3B), there was a modest but significant reduction in the extent 
of IhERG block with dronedarone (see also Table 1).  
 
The F656A mutant is associated with low levels of membrane-
expression; IhERG measurements from F656A were facilitated by 
measuring inward tail currents elicited at -120 mV in the presence of 
higher external (94 mM) [K+] (using the same protocol as for T623A). 
Figure 3C shows the effects of 600nM dronedarone on WT and F656A 
inward IhERG tails, with mean data shown in the bar graph in the right 
panel and summarised in Table 1.  There was a modest but significant 
reduction in block of IhERG by dronedarone for F656A hERG compared 
to its WT control.  
 
Significant reduction of IhERG inhibition by the V659A mutation 
 
The most marked reduction of IhERG inhibition was with the V659A S6 
mutant. Figure 4Ai shows representative traces for WT and V659A IhERG 
in normal 4mM [K+] e solution in the absence and presence of 600nM 
dronedarone. Figure 4Ai shows traces with the entire voltage protocol, 
A 
B 
C 
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whilst Figure 4Aii shows expanded areas of the traces, focusing on the 
inward tail current, during which fractional block was measured.  Figure 
4B and Table 1 show mean data, indicating that the level of inhibition 
was considerably attenuated for this mutation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Representative WT hERG (left panel of Ai) and the S6 mutant V659A (right panel of Ai) in the absence and presence (following 10 min exposure) 
of 600nM of dronedarone (Droned) elicited by the voltage shown under the current traces.  Aii shows expanded views of tail currents aligned with the 
corresponding portion of the voltage protocol (note different timescales for WT and V659A traces). (B) Bar charts displaying the mean fractional block of 
V659A IhERG compared with its WT control. Statistical significance of comparisons of these values is given in Table 1. 
 
Dronedarone docking to the hERG channel 
 
Figure 5 shows low energy score configurations for dronedarone 
(yellow) docked into the open pore of the recently identified, high 
resolution cryo-EM structure of hERG [27] (Figure 5A) and also to a 
hERG homology model built on the MthK channel structure (Figure 5B), 
as this has been found to yield binding configurations that correlate well 
with experimental data [29, 30]. Dronedarone was able to be docked 
within the pore of both the MthK model and the hERG open pore cryo-
EM structure, providing broadly similar conclusions.  In each case low 
energy configurations placed the protonated aliphatic amino group of 
dronedarone near the internal binding site for a K+ ion just below the 
selectivity filter, consistent with competition between drug and K+ ions 
as observed experimentally. The bulky butyl aliphatic groups on the 
protonated nitrogen of dronedarone limited the ability of the drug to 
interact with the side chain hydroxyl groups of S624.  In both the cryo-
EM structure and homology model, the orientation of the V625 residue 
suggests that dronedarone would not interact directly with that residue, 
whilst at least in principle direct interactions with Y652 and F656 could 
occur. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Low energy score configuration for dronedarone (yellow) docked into the open pore of (A) the high resolution cryoEM structure of hERG and 
(B) a hERG homology model built on the MthK channel structure. The location of the S5, S6 and pore helices (PH) are indicated on one of the four subunits. 
The blue star indicates the position of the protonated aliphatic amino group of dronedarone near the binding site for a hydrated K+ ion below the selectivity 
filter. The purple sphere is a K+ ion in the S3 position of the selectivity filter (a water molecule occupies the S4 position). 
 
Discussion 
 
Relevance of potency of dronedarone inhibition of IhERG 
 
The acute effects of dronedarone on IhERG were first investigated using 
Xenopus oocyte expression, yielding an IC50 of 9.2 µM at ambient 
temperature, which is much higher than that subsequently reported from 
experiments using mammalian cell expression and physiological 
temperature and the WT IhERG IC50 value in the present study [15, 16, 
22].  The disparity between the results from Xenopus and mammalian 
cell expression in this regard is likely to be due to the presence of 
vitelline membrane and egg yolk sac in Xenopus oocytes, which can lead 
A i 
A ii 
B 
A B 
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to reduced blocking potency when compared to mammalian cells [15, 
34].  During clinical administration of 400 mg bid, the maximum plasma 
values of dronedarone range from 84 to 147 ng/ml (approximately 151 
to 264 nM), which exceed the WT IhERG IC50 of 42.6 nM in the present 
study [35].  Dronedarone has been reported to produce concentration-
dependent QT interval prolongation in healthy volunteers and cases of 
excessive QTc prolongation, ventricular ectopy and Torsades de Pointes 
have been reported in patients receiving dronedarone [36-38].  In a recent 
preclinical study of dogs receiving dronedarone, the drug was found to 
prolong the Tpeak-Tend interval in a dose-related fashion, suggestive of a 
propensity to prolong transmural dispersion of repolarization and likely 
to result from IKr inhibition [39].  Thus, the fact that dronedarone is a 
potent IhERG blocker likely has relevance to both clinical and 
pathophysiological effects of the drug and it is prudent that the 
concurrent presence of other risk factors for drug-induced QT interval 
prolongation should be taken into account when considering 
administration of this drug [7, 40].  
 
The nature of interactions between dronedarone and the hERG 
channel 
 
The initial Xenopus oocyte data on IhERG block by dronedarone suggested 
that dronedarone may interact with closed, open and inactivated hERG 
channels and revealed some voltage-dependence of inhibition [15].  A 
subsequent mammalian cell study from our laboratory employed a brief 
depolarisation protocol to investigate gated versus closed channel block 
and the results with this were inconsistent with a significant component 
of closed channel block, instead suggesting rapid development of 
channel inhibition on channel gating, with no preference for activated 
over inactivated channels [16].  Similar to the present study, with high 
[K+]e and inward K
+ flux, the extent of dronedarone inhibition of IhERG 
was reduced [16], consistent with drug binding in or close to the ion 
conduction pathway and an electrostatic repulsion or “knock off” effect 
within inward K+ flux [41].   Together with the ability of a profound IhERG 
blocking concentration (4 µM) of dronedarone to inhibit Y652A and 
F656A hERG, this led to the possibility that dronedarone might bind 
relatively high in the channel pore and interact with residues at the base 
of the pore helices (T623, S624, V625), close to the selectivity filter [16].  
Subsequently, we showed that structurally related amiodarone is able to 
interact with the S624 residue as strongly as with Y652 and more 
strongly than with F656 [19]. 
 
In the present study we tested a dronedarone concentration that was >10-
fold the IC50 for outward WT IhERG tail block against pore-helix and S6 
mutations.  Although statistically significant, the reduction from 97% to 
76% inhibition by the Y652A mutation is less extensive than in 
comparable experiments performed with amiodarone [19], whilst the 
reduction to 46% for F656A from 75% from its WT control also 
represents a relatively modest attenuation of block, particularly when 
considered against other high affinity inhibitors (eg [17, 18, 32, 42]).  
Unlike for amiodarone [19], however, the S624A mutation produced no 
significant attenuation of the inhibitory effect of dronedarone, whilst the 
T623A and V625A mutations produced statistically significant, but 
relatively modest reductions in block (Table 1) that appear inconsistent 
with predominant interactions between the drug and pore helical residues 
near the channel’s selectivity filter.  Intriguingly, the mutation with the 
greatest effect on the IhERG inhibitory effect of dronedarone was V659A 
(a reduction to 36% inhibition from 82% for its WT control, Figure 4 
and Table 1).  Indeed, approximation of IC50 values for the different 
hERG mutations (by inserting into the Hill equation the fractional block 
values measured at 600 nM and a Hill coefficient of 1.0) suggested that 
none of the mutations other than V659A would produce a dronedarone 
IC50 >4.5 fold that for the WT channel, whereas for V659A this would 
be approximately 8-fold.  Interestingly, the L532P mutation in the S4 
domain on hERG has been seen to produce an IC50 for dronedarone that 
is 5.3 fold that for WT IhERG [22]. This residue is too far from the pore 
cavity to participate directly in binding drugs that interact with canonical 
binding residues and may exert its effect through an allosteric action in 
positioning key binding residues [22]. Thus, changes in drug potency of 
the order of those seen in the present study do not necessarily indicate a 
direct interaction between the mutated residue and drug binding.  
However, it is noteworthy that a prior in silico study using a modified 
KcsA-based hERG channel model found dronedarone to fit well within 
the channel’s inner cavity with the oxygen atoms of the 
methanesulphonamide group able to interact with side-chains of T623 
and S624 [43].  Our experimental data are compatible with some 
potential interactions with T623, but not with S624.  In that model, 
dronedarone was able also to interact with Y652 and F656 residues and 
the authors commented that partial (as opposed to profound) attenuation 
of block by mutations at these residues [16] might feasibly reflect the 
ability of one aromatic residue to compensate for the other (i.e. loss of 
Y652 interactions in the Y652A hERG mutant may be compensated by 
interactions with F656 and vice versa) [43]. Such compensation has also 
been suggested for other molecules for which mutation of a single 
aromatic residue has comparatively little effect on hERG block [21].  
Our docking simulations were performed with a MthK based hERG 
homology model which has been used previously to study hERG binding 
of a number of drugs and to produce results that accord well with those 
from experimental data [19-21, 24, 29, 30].  We used this model in 
addition to the recent hERG structure obtained from cryo-EM [27] 
because recent data raise the possibility that the hERG structure may 
have been captured in a conformation that is not optimal for studying 
high affinity drug binding [30]. In both the MthK model and the hERG 
open pore cryo-EM structure (Figure 5) low energy configurations 
placed the protonated aliphatic amino group of dronedarone near the 
internal binding site for a K+ ion just below the selectivity filter, 
consistent with competition between drug and K+ ions as observed 
experimentally. Unlike with amiodarone [19], the bulky butyl aliphatic 
groups on the protonated nitrogen of dronedarone limit interaction with 
the side chain hydroxyl groups of S624 and this may explain the absence 
of effect of S624A on dronedarone block. In neither the MthK model nor 
the cryoEM structure could dronedarone make direct interactions with 
the V659 side chain, which is oriented away from the channel pore 
towards the S5 helix. The moderate (approx. 8-fold) effect of V659A is 
therefore most likely due to an effect on the configuration of the pore as 
a result of altered packing at the S5-S6 interface that also results in 
perturbed channel gating in hERG V659A [44]. The modest effect on 
channel block in both the Y652A and F656A hERG mutants is more 
difficult to explain in the context of docking since the drug should come 
into contact at least with Y652 in the cryo-EM structure and with both 
Y652 and F656 in the MthK model.  As discussed above, one potential 
explanation for this is reciprocal compensating interactions involving 
these residues. Accordingly, future work is warranted to determine 
whether combining mutations at Y652 and F656 is able to eliminate high 
affinity IhERG block by dronedarone, or whether alternative potential 
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binding residues to those studied here (eg [45]) contribute to the drug’s 
potent inhibitory action on IhERG. 
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